GSK's Sandy Macrae On R&D For Emerging Markets: An Interview With PharmAsia News (Part 1 Of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK's Senior VP Asia Pacific, Japan, and Emerging Markets R&D has been busy pitching the company's established presence in emerging markets to companies looking to expand beyond traditional markets, and even some that aren't.
You may also be interested in...
Amgen's Prolia Bags Favorable Draft Appraisal From UK Medicines Watchdog
NICE considers denosumab a cost-effective use of NHS resources for second-line osteoporosis use.
Red Hot Deal For Red Heart Pill - Dr. Reddy's In Talks With GSK For Combination Heart Drug
MUMBAI - India's Dr. Reddy's Laboratories and pharmaceutical major GlaxoSmithKline are in active discussions to partner on marketing a uniquely designed combination drug that can combat cardiovascular and cerebrovascular diseases and will be priced "very economically.
GSK Sees Emerging Market Opportunity In Thinking Locally, Developing Locally
SINGAPORE - GSK APJEM R&D is pretty hefty as far as acronyms go, but GlaxoSmithKline's Judith Hills wants to make sure observers do not over look the research and development title in the new GSK division